Vimkunya is supplied as an injectable suspension; the vaccine is administered intramuscularly as a single 0.8 mL dose.

Explore the evolution of vaccine technology from Jenner to mRNA, highlighting India's role in COVID-19 vaccine development.

The US Food and Drug Administration (FDA) has granted accelerated approval to Vimkunya™, a recombinant chikungunya vaccine, ...

Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat chronic infections for the first time.

DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced the peer-reviewed publication entitled: ...

A multi-national, multi-institutional study investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.

A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...

ImmunityBio, Inc. , a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded access program (EAP) that will bring a vital alternative ...

The Recombinant DNA Technology Market size is expected to be worth around USD 1288.5 Bn by 2032 from USD 786.7 Bn in 2023, growing at a CAGR of 5.8% As scientific and technological advancements ...

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger ...

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger travelers.On track for commercial launch in the U.S. in the ...